Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|5|674-679

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.5, 2018-03, pp. : 674-679

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post‐transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 32, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1004-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1004-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 421-431

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite